Inhibikase Therapeutics Inc Cash Flow-to-Debt Ratio
Inhibikase Therapeutics Inc cash flow-to-debt ratio. Inhibikase Therapeutics Inc (IKT) has a Cash Flow-to-Debt Ratio of -1.58x as of September 2025, meaning its operating cash flow of $-10.59 Million could theoretically repay -2% of its total liabilities ($6.70 Million) in one year. See IKT free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Inhibikase Therapeutics Inc (2016–2024)
Cash flow-to-debt ratio of Inhibikase Therapeutics Inc from 2016 to 2024. Historical debt coverage capacity for Inhibikase Therapeutics Inc across 9 annual periods. Check Inhibikase Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Inhibikase Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2016–2024)
Inhibikase Therapeutics Inc cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for Inhibikase Therapeutics Inc. For the full cash flow conversion analysis, see Inhibikase Therapeutics Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -5.13x | $-19.15 Million | $3.73 Million | ▼ -0.1% |
| 2023 | -5.13x | $-18.09 Million | $3.53 Million | ▼ -15.2% |
| 2022 | -4.45x | $-17.35 Million | $3.90 Million | ▼ -26.1% |
| 2021 | -3.53x | $-14.30 Million | $4.05 Million | ▼ -1460.7% |
| 2020 | -0.23x | $-1.13 Million | $5.00 Million | ▼ -202.4% |
| 2019 | -0.07x | $-338.29K | $4.53 Million | ▼ -137.9% |
| 2018 | 0.20x | $714.99K | $3.62 Million | ▲ +369.4% |
| 2017 | -0.07x | $-126.39K | $1.73 Million | ▼ -275.0% |
| 2016 | -0.02x | $-29.57K | $1.51 Million | — |